ABSTRACT Soybean seeds (Glycine max) were dried under real scale conditions to different final moisture content (m.c.) (9.1, 9.7, 10.9 %, and control with 16.2 %) and processed through extruding-expelling. Results indicated that soybean seed m.c. affected the composition of the soybean expeller and, thus, the oil extraction efficiency (OEE), which increased as the seed m.c. decreased. A polynomic model was proposed for predicting OEE as a function of soybean m.c., indicating that drying soybean to 10 % resulted in an OEE of approximately 65 %. A thin layer drying experiment of soybean seeds indicated that the protein dispersibility index (PDI) was not affected as regards drying air temperatures up to approximately 69 °C, and a bi-linear model with a non-pre-established break point was fitted. The real scale drying treatment in a rack type dryer (mixed flow) did not show any effect (p > 0.05) on the PDI at 80 °C, while at 115 °C a reduction (p < 0.05) was observed (PDI reduction was 0.8 and 2.1 percentage points, respectively).

Trichomonas vaginalis é o agente etiológico da tricomoníase, a doença sexualmente transmissível (DST) não-viral mais comum no mundo. Esse protozoário flagelado atinge o parasitismo com sucesso em um ambiente hostil através dos vários mecanismos pelos quais estabelece sua patogenicidade e também por sua capacidade de evadir a resposta imune do hospedeiro. A infecção apresenta uma ampla variedade de manifestações clínicas, desde quadro assintomático até severa vaginite. A tricomoníase tem sido associada à transmissão do vírus da imunodeficiência humana (HIV), à doença inflamatória pélvica, ao câncer cervical, à infertilidade, ao parto prematuro e ao baixo peso de bebês nascidos de mães infectadas. A investigação laboratorial é essencial na diagnose dessa patogenia, uma vez que leva ao tratamento apropriado e facilita o controle da propagação da infecção. A prevalência mundial anual da tricomoníase é de 180 milhões de casos, e na Europa é responsável por 41% dos casos de vaginite. A terapia da tricomoníase inclui as mesmas medidas profiláticas destinadas às outras DSTs, como prática de sexo seguro e uso de preservativos. O metronidazol é o medicamento de escolha no tratamento da tricomoníase, entretanto, devido à ineficácia dos tratamentos de dose única e ao iminente surgimento de cepas resistentes, outras alternativas terapêuticas estão sendo investigadas.

Trichomonas vaginalis is the aethiologic agent of trichomoniasis, the sexually transmitted disease (STD) non-viral most common in the world. This flagellate protozoan successfully reaches the parasitism in a hostile environment through some mechanisms which establish its pathogenicity and also through its capacity to evade the host immune response. Trichomoniasis presents a large variety of clinical manifestations, from a totally asymptomatic infection to severe vaginitis. It has been associated to the increase in transmission of the human immunodeficiency virus (HIV), pelvic inflammatory disease, cervical cancer, infertility, and premature delivery and low birth weight of children born from infected mothers. The laboratorial inquiry is essential in diagnosis of this STD, leads to the appropriate treatment and facilitates the control of the spread of T. vaginalis infection. The annual world prevalence of trichomoniasis is 180 million cases and in Europe it is responsible for 41% of vaginitis cases. The treatment of trichomoniasis includes the same profilatic means devoted to others STDs, such as secure sex practice and preservative use. Metronidazole is the choose for the treatment of trichomoniasis, however, due to the fail in the single dose treatment and the imminent appearance of resistant strains, other therapeutic alternatives are been investigated.